Regor announces the first patient dosed in the U.S. in the Phase II clinical trial for RGT-075, a novel small molecule GLP-1R agonist

Regor Therapeutics Group, a clinical-stage biotech company focusing on immunology, oncology, and metabolic disorders, announced today that the first patient has been dosed in the Phase II clinical trial of the Company’s novel oral small molecule GLP-1 receptor agonist RGT-075 in the U.S.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a well-characterized class of hypoglycemic agents used to treat patients with type 2 diabetes mellitus (T2DM). RGT-075 is a novel oral small molecule GLP-1 receptor agonist. The Phase II clinical trial is conducted in the form of randomized, multi-blind, multi-center placebo-controlled trial, exploring the efficacy and safety of RGT-075 in patients with type 2 diabetes mellitus who have poor glycemic control following metformin treatment. The first patient dosing of this trial has been completed in the U.S. The study was officially launched on March 30, 2022.

According to the International Diabetes Federation (IDF) Diabetes Survey 2021, there are an estimated 537 million adults with diabetes worldwide, and this number is expected to reach 643 million by 2030 and 784 million by 2045. Type 2 diabetes is the predominant type of diabetes and will continue to increase with rising rates of obesity and ageing.

About Regor Therapeutics Group

Regor Therapeutics Group is a clinical stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary rCARD^TM (Computer Accelerated Rational Discovery) Platform. The company focuses mainly on three therapeutic areas, oncology, immunology, and metabolic disorders. By seamlessly integrating rCARD^TM with structural biology, computational biology, computational chemistry and other disciplines, Regor has successfully assembled a world-class scientific team and established a highly efficient new drug innovation engine to enable the discovery and development of best- and first-in-class molecules.